Herbal remedy investigation
This article was originally published in The Tan Sheet
FDA is investigating the toxic potential of Chinese herbal remedy Jin Bu Haun, which is used as a sedative and analgesic, according to the Centers for Disease Control and Prevention's Dec. 3 Morbidity and Mortality Weekly Report. CDC noted that in July and August 1993, three women in Los Angeles developed acute hepatitis after ingesting Jin Bu Huan, which has previously been associated with the onset of acute hepatitis. CDC recommended in the Aug. 27 MMWR that traditional ethnic remedies (including Jin Bu Huan) should-be sold in child-proof packaging due to their toxic potential. CDC also had reported that in 1993 three children in Colorado experienced central nervous system and respiratory depression leading to life-threatening bradycardia after an unintentional overdose of Jin Bu Huan.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC